Guo, Si-Kun http://orcid.org/0000-0003-1637-5299
Liu, Chu-Xiao http://orcid.org/0000-0002-6725-8327
Xu, Yi-Feng http://orcid.org/0000-0002-5111-8565
Wang, Xiao
Nan, Fang
Huang, Youkui
Li, Siqi
Nan, Shan
Li, Ling
Kon, Edo
Li, Chen
Wei, Meng-Yuan
Su, Rina
Wei, Jia
Peng, Shiguang
Ad-El, Nitay http://orcid.org/0000-0002-1936-8628
Liu, Jiaquan
Peer, Dan http://orcid.org/0000-0001-8238-0673
Chen, Ting http://orcid.org/0000-0002-7404-4538
Yang, Li http://orcid.org/0000-0001-8833-7473
Chen, Ling-Ling http://orcid.org/0000-0001-9501-0305
Article History
Received: 20 October 2023
Accepted: 12 March 2024
First Online: 23 April 2024
Competing interests
: L.-L.C., S.-K.G., C.-X.L., S.L. and Y.-F.X. are named as inventors on patents related to circRNA held by CAS CEMCS. L.-L.C. is a scientific co-founder of RiboX Therapeutics. D.P. receives licensing fees (to patents on which he was an inventor) from, invested in, consults (or on scientific advisory boards or boards of directors) for, lectured (and received a fee) or conducts sponsored research at TAU for the following entities: ART Biosciences, BioNtech SE, Earli Inc., Kernal Biologics, Geneditor Biologics, Newphase Ltd, NeoVac Ltd, RiboX Therapeutics, Roche, SirTLabs Corporation and Teva Pharmaceuticals Inc.